Biotech/Pharma Industry Survival

2020 Vision: Will the Biotech/Pharma Industry Foresee & Survive the Next Decade? How Global Economic, Business & Regulatory Trends will Terraform the Biotech/Pharma Ecosphere

David Palella

Thursday, December 2, 2010, 5:30-8:30 pm


Healthcare spending trends in the U.S. are unsustainable. Deficit spending and imminent debasement of the Dollar concurrent with high interest rates worldwide will lead to material cuts in healthcare spending in the U.S. and Europe from 2012 through 2020. Certain currencies will become very cheap, others very expensive. Companies with R&D or products in an expensive currency will experience significant competitive disadvantages or sales declines, and be forced to out-source to cheaper locations such as Vietnam, Indonesia, and 2nd-tier Indian & Chinese provinces/cities, thus causing more job losses in their home countries.

Add patent expirations, the biosimilars Cambrian Explosion, new FDA regulatory strictures for personalized medicine, higher pharmaco-economic hurdles imposed by payors (government and private), increasingly frequent global black swan events -- and the U.S. Biotech/Pharma industry is an endangered species. Pharma & Biotech companies in the U.S. will continue to merge and "right size" to project the illusion of “progress” and to “manage earnings”. And smaller biotech companies and their employees & investors will have to "think globally and act locally", and work much harder than they have to date in order to compete and survive.

David Palella is President of BioScience Ventures, a consulting firm for global strategic alliances, business development and M&A advisory in biopharmaceuticals. David’s extensive business expertise is in the areas of oncology, autoimmune & infectious diseases, therapeutic antibodies & proteins, diagnostics and specialty pharmaceuticals. A private investor for >30 years, David holds stock positions, warrants/options in several private American biotech companies.

Past and current clients of BioScience Ventures include ICOS; Takeda Chemical Industries; Biosite; Diversa; Maxygen; Prometheus Labs; Myriad Genetics; Chiome Biosciences; Karo Bio AB; Novacta Biosystems; Chenomx; Astute Medical; Avid Bioservices; SangStat; EPIcyte; Structural Bioinformatics; CombiChem; Eisai; Hisamitsu; Mitsubishi Chemical; Nippon Kayaku; Sumitomo Chemical; and Teijin. David has facilitated the closing of dozens of in- and out-licensing deals from no-cash barter deals to US$ 15 – 20m.

David received an MBA, BS and BA (summa cum laude, Phi Beta Kappa & Phi Kappa Phi) from Arizona State University and an M.S. in Japanese Business Studies (MSJBS) from Chaminade University in Honolulu, Hawaii.

Registration: () $20 online (until December 1), $10 student / in transition / affiliate $25 onsite, $15 student/ in transition / affiliate

choose ticket

Location: Knobbe Martens

12790 El Camino Real, San Diego, CA 92130

Many thanks to Rose Thiessen for being our gracious host at Knobbe Martens.

From I-5 South:

  • Take Del Mar Heights Road Exit
  • Turn Left on Del Mar Heights Road
  • Turn Right on El Camino Real
  • 12970 El Camino Real is on the Right
From I-5 North:

  • Take Del Mar Heights Road Exit
  • Turn Right on Del Mar Heights Road
  • Turn Right on El Camino Real
  • 12970 El Camino Real is on the Right